Evolve Private Wealth LLC Takes Position in Medpace Holdings, Inc. $MEDP

Key Points

• Evolve Private Wealth LLC acquired 2,618 Medpace shares worth approximately $1.386 million in the second quarter. Institutional investors collectively own 77.98% of the company.
• Medpace reported quarterly earnings of $4.25 per share, beating estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25 to $17.95.
• Medpace shares opened at $620.75, near their 52-week high of $677.90, but analysts maintain a consensus “Hold” rating with an average price target of $584.18; insiders sold $71.7 million of stock over the past 90 days.

Evolve Private Wealth LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,618 shares of the company's stock, valued at approximately $1,386,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new stake in Medpace during the second quarter worth about $1,323,047,000. AQR Capital Management LLC boosted its stake in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company's stock valued at $758,061,000 after purchasing an additional 324,293 shares in the last quarter. Wasatch Advisors LP grew its stake in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC increased its holdings in Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock valued at $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company's stock valued at $276,313,000 after buying an additional 85,517 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Insider Buying and Selling

In other Medpace news, Director Cornelius P. Mccarthy III sold 1,140 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director directly owned 12,275 shares of the company's stock, valued at $7,430,916.75. The trade was a 8.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Brian T. Carley sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares in the company, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 122,261 shares of company stock valued at $71,729,129 over the last ninety days. Insiders own 20.50% of the company's stock.

Medpace Price Performance

Medpace stock opened at $620.75 on Monday. The firm has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15. The company's 50 day simple moving average is $550.16 and its 200 day simple moving average is $492.03. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. BMO Capital Markets upped their price objective on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and increased their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. TD Cowen lifted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source